<p>公司們經常宣佈股票拆分，而截至目前，今年已經有多家知名公司將其股票拆分成更小的份額。</p>
<p><strong>沃爾瑪</strong> (NYSE:WMT) 在二月份進行了股票拆分，<strong>墨西哥捲餅餐廳</strong> (NYSE:CMG) 在六月份進行了 <strong>紐約證券交易所</strong> 歷史上最大的拆分，拆分比例為 50 比 1，而 <strong>英偉達</strong> (NASDAQ:NVDA) 在一個月後進行了 4 比 1 的拆分。</p>
<p>雖然有幾家公司可能會在下一個股票拆分公告中脱穎而出，但 <strong>Vertex Pharmaceuticals</strong> (NASDAQ:VRTX) 可能會在 11 月 4 日的財報中超越它們。</p>
<h2>24/7 Wall St. 見解：</h2>
<ul>
<li><strong>Vertex Pharmaceuticals</strong> (VRTX) 在囊性纖維化市場幾乎擁有壟斷地位，提供兩種療法，治療約 75% 的患者。</li>
<li>由於 VRTX 股票的交易價格為每股 475 美元，遠高於更大的競爭對手，這家生物技術公司可能會選擇讓其股票對投資者更具可及性。</li>
<li>如果你在尋找一些具有巨大潛力的股票，確保獲取我們全新的 “下一個英偉達” 報告的免費副本。報告中介紹了一隻我們相信具有 10 倍潛力的軟件股票。</li>
</ul>
<h2>更小的蛋糕切片</h2>
<p><img src="https://imageproxy.pbkrs.com/https://247wallst.com/wp-content/uploads/2020/08/imageForEntry1-Vx1.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://247wallst.com/wp-content/uploads/2020/08/imageForEntry1-Vx1.jpg"/></p>
<p>儘管股票拆分被視為看漲信號，但這並不意味着投資者不需要進行盡職調查。</p>
<p>股票拆分當然是企業的非事件。因為它們只是改變了流通股數量和股價，對公司的基本面沒有實際影響。</p>
<p>然而，投資者對此情有獨鍾！管理層將其視為未來增長的看漲信號，並通過人為降低股價，讓更多投資者有機會購買。</p>
<p>有一些證據表明這一點。以往股票拆分的數據表明，公司在事件發生後的 12 個月內增長了 25% 到 30%。但拆分只是反映了強勁的過去表現，並沒有創造任何新的股東價值。投資者仍需仔細審查業務，以確保其將保持在同一軌跡上。</p>
<p>例如，本月早些時候，<strong>超微計算機</strong> (NASDAQ:SMCI) 完成了 10 比 1 的股票拆分。拆分前交易接近 416 美元的股票，現在的價格為每股 41.60 美元。然而，SMCI 在公告前的交易價格已超過 600 美元，但令人失望的財報、空頭報告指出潛在的會計不規範，以及司法部對其會計實踐的調查消息，都使其股價大幅下跌。</p>
<p>而現在，其會計事務所安永已辭職，表示不想再接手超微的賬簿。該消息使股價再次暴跌 33%。SMCI 的股價自 3 月高點以來已下跌 73%。股票拆分並不總是意味着好消息。</p>
<h2>小池塘裏的大魚</h2>
<p><img src="https://imageproxy.pbkrs.com/https://247wallst.com/wp-content/uploads/2019/12/imageforentry12-0wh.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://247wallst.com/wp-content/uploads/2019/12/imageforentry12-0wh.jpg"/></p>
<p>Vertex Pharmaceuticals 是治療囊性纖維化的無可爭議的領導者。</p>
<p>Vertex Pharmaceuticals 並未面臨類似的醜聞。這家生物技術公司在過去三年中上漲了 162%，其在囊性纖維化治療中的幾乎壟斷地位持續推動着其業務增長。</p>
<p>在北美、歐洲和澳大利亞估計有 92,000 名囊性纖維化患者，Vertex 治療了近四分之三的患者。其主要療法 Trikafta 和 Kaftrio 在 2024 年上半年產生了 49 億美元的銷售額，比去年同期增長了 14%。這兩種藥物佔 Vertex 總收入的 92%。</p>
<p>這家生物技術公司的風險在於其定義過於狹窄。由於專注於單一疾病，且所有銷售依賴於一兩種藥物，若競爭對手開發出新的、更好的治療方案，集中風險將加大。</p>
<p>這就是為什麼 Vertex 希望拓寬視野，進入罕見疾病藥物市場。它與 <strong>CRISPR Therapeutics</strong> (NASDAQ:CRSP) 合作，幫助基因編輯療法 Casgevy 於去年 12 月獲得食品和藥物管理局的批准，用於治療輸血依賴性β-地中海貧血（TDT）和鐮狀細胞病（SCD）。該藥物具有十億美元的潛在市場。</p>
<p>雖然 CRISPR 將獲得 Casgevy 利潤的絕大部分，但 Vertex 將獲得 40% 的利潤。它還將獲得 40% 的研發費用的報銷。</p>
<h2>行動時刻</h2>
<p>VRTX 的股票交易價格為每股 475 美元，過去一年上漲了 33%。現在進行股票拆分可能是合理的，以增加其流動性，並通過縮小買賣差價來實現生物技術公司股票的更有效定價。</p>
<p>隨着股票對更廣泛的投資者羣體變得更加可及，可能會提升其交易量。</p>
<p>Vertex Pharmaceuticals 並不陌生於股票拆分，儘管自上次拆分以來已經過去很長時間。這家生物技術公司今天與 2000 年進行 2 比 1 拆分時相比，已經大為不同。</p>
<p>憑藉強大的、盈利的囊性纖維化業務、在新市場的潛在增長、豐富的臨牀試驗療法管道，以及遠超 <strong>安進</strong> (NASDAQ:AMGN) 和 <strong>生物基因</strong> (NASDAQ:BIIB) 的股價，VRTX 可能成為下一個進行股票拆分的公司。</p>
<h2><strong>投資的基本技巧（贊助）</strong></h2>
<p>財務顧問可以幫助你瞭解投資物業的優缺點。尋找合格的財務顧問並不困難。SmartAsset 的免費工具可以將你與最多三位服務於你所在地區的財務顧問匹配，你可以免費面試這些顧問，以決定哪個最適合你。如果你準備找到一位可以幫助你實現財務目標的顧問，現在就開始吧。</p>
<p>投資房地產可以使你的投資組合多樣化。但拓寬視野可能會增加額外成本。如果你是希望降低開支的投資者，可以考慮查看在線經紀公司。它們通常提供低投資費用，幫助你最大化利潤。</p>
<p>預測：福泰製藥 (VRTX) 可能成為下一個拆股股票，首發於 24/7 Wall St..</p>

福泰制藥

<p>Vertex Pharmaceuticals (VRTX) 被預測為可能進行股票拆分的候選者，特別是在它於 11 月 4 日發佈財報之際。該公司在囊性纖維化市場中佔據強勢地位，約 75% 的患者使用其領先的治療方案。儘管股票拆分通常被視為看漲信號，但並不會改變公司的基本面。VRTX 在過去三年中實現了 162% 的顯著增長，但由於其對囊性纖維化治療的狹窄關注，面臨一定風險。該公司還通過與 CRISPR Therapeutics 的合作，探索在罕見疾病市場的機會</p>

<p>Companies announce stock splits all the time, and so far this year a number of high profile companies have divvied up their shares into smaller slices.</p>
<div class="lb-trans"><p>公司們經常宣佈股票拆分，而截至目前，今年已經有多家知名公司將其股票拆分成更小的份額。</p>
</div><p><strong>Walmart</strong> (NYSE:WMT) split its stock in February, <strong>Chipotle Mexican Grill</strong> (NYSE:CMG) did the largest split in <strong>NYSE</strong> history in June when it split its shares 50-to-1, and <strong>Nvidia</strong> (NASDAQ:NVDA) split its stock 4-to-1 a month later.</p>
<div class="lb-trans"><p><strong>沃爾瑪</strong> (NYSE:WMT) 在二月份進行了股票拆分，<strong>墨西哥捲餅餐廳</strong> (NYSE:CMG) 在六月份進行了 <strong>紐約證券交易所</strong> 歷史上最大的拆分，拆分比例為 50 比 1，而 <strong>英偉達</strong> (NASDAQ:NVDA) 在一個月後進行了 4 比 1 的拆分。</p>
</div><p>While there are several candidates to make the next stock split announcement, <strong>Vertex Pharmaceuticals</strong> (NASDAQ:VRTX) may just trump them all when it reports earnings on Nov. 4.</p>
<div class="lb-trans"><p>雖然有幾家公司可能會在下一個股票拆分公告中脱穎而出，但 <strong>Vertex Pharmaceuticals</strong> (NASDAQ:VRTX) 可能會在 11 月 4 日的財報中超越它們。</p>
</div><h2>24/7 Wall St. Insights:</h2>
<ul>
<li><strong>Vertex Pharmaceuticals</strong> (VRTX) has a virtual monopoly on the cystic fibrosis market with two therapies treating about 75% of all patients.</li>
<li>With VRTX stock trading at $475 per share, well ahead of even larger rivals, the biotech may choose to make its shares more accessible to investors.</li>
<li>If you’re looking for some stocks with huge potential, make sure to grab a free copy of our brand-new “The Next NVIDIA” report. It features a software stock we’re confident has 10X potential.</li>
</ul>
<div class="lb-trans"><h2>24/7 Wall St. 見解：</h2>
<ul>
<li><strong>Vertex Pharmaceuticals</strong> (VRTX) 在囊性纖維化市場幾乎擁有壟斷地位，提供兩種療法，治療約 75% 的患者。</li>
<li>由於 VRTX 股票的交易價格為每股 475 美元，遠高於更大的競爭對手，這家生物技術公司可能會選擇讓其股票對投資者更具可及性。</li>
<li>如果你在尋找一些具有巨大潛力的股票，確保獲取我們全新的 “下一個英偉達” 報告的免費副本。報告中介紹了一隻我們相信具有 10 倍潛力的軟件股票。</li>
</ul>
</div><h2>Smaller slices of the pie</h2>
<div class="lb-trans"><h2>更小的蛋糕切片</h2>
</div><p><img src="https://imageproxy.pbkrs.com/https://247wallst.com/wp-content/uploads/2020/08/imageForEntry1-Vx1.jpg" alt="" original-src="https://247wallst.com/wp-content/uploads/2020/08/imageForEntry1-Vx1.jpg"/></p>
<p>Just because a stock split is seen as a bullish signal doesn’t mean investors don’t need to still perform their due diligence</p>
<div class="lb-trans"><p>儘管股票拆分被視為看漲信號，但這並不意味着投資者不需要進行盡職調查。</p>
</div><p>Stocks splits, of course, are a corporate non-event. Because they only change the number of shares outstanding — and the stock price — there is no real impact on the underlying fundamentals of the company.</p>
<div class="lb-trans"><p>股票拆分當然是企業的非事件。因為它們只是改變了流通股數量和股價，對公司的基本面沒有實際影響。</p>
</div><p>Yet investors love them! They are viewed as a bullish signal by management that more growth is on the way and by artificially lowering the share price, more investors will have an opportunity to buy them.</p>
<div class="lb-trans"><p>然而，投資者對此情有獨鍾！管理層將其視為未來增長的看漲信號，並通過人為降低股價，讓更多投資者有機會購買。</p>
</div><p>There is some evidence this is true. Data from previous stock splits suggests companies grow between 25% and 30% in the 12 months after the event. But a split is only reflecting strong past performance and not creating any new shareholder value. Investors still need to scrutinize the business to ensure it will remain on the same trajectory.</p>
<div class="lb-trans"><p>有一些證據表明這一點。以往股票拆分的數據表明，公司在事件發生後的 12 個月內增長了 25% 到 30%。但拆分只是反映了強勁的過去表現，並沒有創造任何新的股東價值。投資者仍需仔細審查業務，以確保其將保持在同一軌跡上。</p>
</div><p>For example, earlier this month <strong>Super Micro Computer</strong> (NASDAQ:SMCI) completed a 10-for-1 stock split. Shares that had been trading near $416 pre-split were now going for $41.60 per share. Yet SMCI had been trading well north of $600 a share prior to the announcement, but disappointing earnings, a short-seller’s report calling out potential accounting irregularities, and news of a Justice Dept. probe into its accounting practices all sent its shares careening lower.</p>
<div class="lb-trans"><p>例如，本月早些時候，<strong>超微計算機</strong> (NASDAQ:SMCI) 完成了 10 比 1 的股票拆分。拆分前交易接近 416 美元的股票，現在的價格為每股 41.60 美元。然而，SMCI 在公告前的交易價格已超過 600 美元，但令人失望的財報、空頭報告指出潛在的會計不規範，以及司法部對其會計實踐的調查消息，都使其股價大幅下跌。</p>
</div><p>And now its accounting firm EY has resigned saying it doesn’t want to touch Super Micro’s books anymore. The stock tanked another 33% on the news. SMCI stock is down 73% from its March peak. Stock splits don’t always mean good news.</p>
<div class="lb-trans"><p>而現在，其會計事務所安永已辭職，表示不想再接手超微的賬簿。該消息使股價再次暴跌 33%。SMCI 的股價自 3 月高點以來已下跌 73%。股票拆分並不總是意味着好消息。</p>
</div><h2>The big fish in a small pond</h2>
<div class="lb-trans"><h2>小池塘裏的大魚</h2>
</div><p><img src="https://imageproxy.pbkrs.com/https://247wallst.com/wp-content/uploads/2019/12/imageforentry12-0wh.jpg" alt="" original-src="https://247wallst.com/wp-content/uploads/2019/12/imageforentry12-0wh.jpg"/></p>
<p>Vertex Pharmaceuticals is the undisputed leader in treating cystic fibrosis</p>
<div class="lb-trans"><p>Vertex Pharmaceuticals 是治療囊性纖維化的無可爭議的領導者。</p>
</div><p>Vertex Pharmaceuticals isn’t facing any similar scandals. The biotech is up 162% over the past three years as its virtual monopoly on cystic fibrosis treatment continues driving its business higher.</p>
<div class="lb-trans"><p>Vertex Pharmaceuticals 並未面臨類似的醜聞。這家生物技術公司在過去三年中上漲了 162%，其在囊性纖維化治療中的幾乎壟斷地位持續推動着其業務增長。</p>
</div><p>Of the estimated 92,000 patients with CF in North America, Europe and Australia, Vertex treats nearly three-quarters of them. Its leading therapies are Trikafta and Kaftrio that have generated $4.9 billion in sales in the first half of 2024, a 14% increase over the year-ago period. The duo account for 92% of Vertex’s total revenue.</p>
<div class="lb-trans"><p>在北美、歐洲和澳大利亞估計有 92,000 名囊性纖維化患者，Vertex 治療了近四分之三的患者。其主要療法 Trikafta 和 Kaftrio 在 2024 年上半年產生了 49 億美元的銷售額，比去年同期增長了 14%。這兩種藥物佔 Vertex 總收入的 92%。</p>
</div><p>The risk for the biotech comes in being so narrowly defined. By being laser-focused on a single condition, and having all of its sales dependent upon one or two drugs, the concentration risk is heightened in the event a rival develops a new, better treatment.</p>
<div class="lb-trans"><p>這家生物技術公司的風險在於其定義過於狹窄。由於專注於單一疾病，且所有銷售依賴於一兩種藥物，若競爭對手開發出新的、更好的治療方案，集中風險將加大。</p>
</div><p>That’s why Vertex is looking to broaden its outlook to enter the rare disease drug market. It has partnered with <strong>CRISPR Therapeutics</strong> (NASDAQ:CRSP), which helped get the gene-editing therapy Casgevy approved by the Food &amp; Drug Administration last December for the treatment of transfusion-dependent beta-thalassemia (TDT) and sickle cell disease (SCD). It has billion-dollar blockbuster potential.</p>
<div class="lb-trans"><p>這就是為什麼 Vertex 希望拓寬視野，進入罕見疾病藥物市場。它與 <strong>CRISPR Therapeutics</strong> (NASDAQ:CRSP) 合作，幫助基因編輯療法 Casgevy 於去年 12 月獲得食品和藥物管理局的批准，用於治療輸血依賴性β-地中海貧血（TDT）和鐮狀細胞病（SCD）。該藥物具有十億美元的潛在市場。</p>
</div><p>While CRISPR will receive the lion’s share of the profits for Casgevy, Vertex will get 40% of them. It also gets reimbursed for 40% of the research and development costs that went into the drug.</p>
<div class="lb-trans"><p>雖然 CRISPR 將獲得 Casgevy 利潤的絕大部分，但 Vertex 將獲得 40% 的利潤。它還將獲得 40% 的研發費用的報銷。</p>
</div><h2>Time for action</h2>
<div class="lb-trans"><h2>行動時刻</h2>
</div><p>Shares of VRTX trade $475 each, up 33% over the past year. A stock split could make sense now to increase its liquidity and allow for more efficient pricing of the biotech’s shares by narrowing the bid-ask price.</p>
<div class="lb-trans"><p>VRTX 的股票交易價格為每股 475 美元，過去一年上漲了 33%。現在進行股票拆分可能是合理的，以增加其流動性，並通過縮小買賣差價來實現生物技術公司股票的更有效定價。</p>
</div><p>As the stock becomes more accessible to a broader range of investors, it has the potential to boost its trading volume.</p>
<div class="lb-trans"><p>隨着股票對更廣泛的投資者羣體變得更加可及，可能會提升其交易量。</p>
</div><p>Vertex Pharmaceuticals isn’t a stranger to splitting its stock, though it is a long time since the last split occurred. The biotech is a much different company today than it was in 2000 when it split its shares 2-for-1.</p>
<div class="lb-trans"><p>Vertex Pharmaceuticals 並不陌生於股票拆分，儘管自上次拆分以來已經過去很長時間。這家生物技術公司今天與 2000 年進行 2 比 1 拆分時相比，已經大為不同。</p>
</div><p>With a strong, profitable CF business, potential growth in new markets, a robust pipeline of therapies in clinical trials, and a stock price well ahead of rivals like <strong>Amgen</strong> (NASDAQ:AMGN) and <strong>Biogen</strong> (NASDAQ:BIIB), VRTX could be the next stock split stock.</p>
<div class="lb-trans"><p>憑藉強大的、盈利的囊性纖維化業務、在新市場的潛在增長、豐富的臨牀試驗療法管道，以及遠超 <strong>安進</strong> (NASDAQ:AMGN) 和 <strong>生物基因</strong> (NASDAQ:BIIB) 的股價，VRTX 可能成為下一個進行股票拆分的公司。</p>
</div><h2><strong>Essential Tips for Investing (Sponsored)</strong></h2>
<div class="lb-trans"><h2><strong>投資的基本技巧（贊助）</strong></h2>
</div><p>A financial advisor can help you understand the advantages and disadvantages of investment properties. Finding a qualified financial advisor doesn’t have to be hard. SmartAsset’s free tool matches you with up to three financial advisors who serve your area, and you can interview your advisor matches at no cost to decide which one is right for you. If you’re ready to find an advisor who can help you achieve your financial goals, get started now.</p>
<div class="lb-trans"><p>財務顧問可以幫助你瞭解投資物業的優缺點。尋找合格的財務顧問並不困難。SmartAsset 的免費工具可以將你與最多三位服務於你所在地區的財務顧問匹配，你可以免費面試這些顧問，以決定哪個最適合你。如果你準備找到一位可以幫助你實現財務目標的顧問，現在就開始吧。</p>
</div><p>Investing in real estate can diversify your portfolio. But expanding your horizons may add additional costs. If you’re an investor looking to minimize expenses, consider checking out online brokerages. They often offer low investment fees, helping you maximize your profit.</p>
<div class="lb-trans"><p>投資房地產可以使你的投資組合多樣化。但拓寬視野可能會增加額外成本。如果你是希望降低開支的投資者，可以考慮查看在線經紀公司。它們通常提供低投資費用，幫助你最大化利潤。</p>
</div><p>The post Prediction: Vertex Pharmaceuticals (VRTX) Could Be The Next Stock Split Stock appeared first on 24/7 Wall St..</p>
<div class="lb-trans"><p>預測：福泰製藥 (VRTX) 可能成為下一個拆股股票，首發於 24/7 Wall St..</p>
</div>

預測：福泰製藥（VRTX）可能是下一個進行股票拆分的公司